BIO-TECHNE Corp Stock Nasdaq
Equities
US8783771004
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2024 * | 1.16B 1.59B | Sales 2025 * | 1.25B 1.71B | Capitalization | 11.32B 15.49B |
---|---|---|---|---|---|
Net income 2024 * | 180M 246M | Net income 2025 * | 228M 312M | EV / Sales 2024 * | 9.91 x |
Net Debt 2024 * | 166M 227M | Net cash position 2025 * | 85.4M 117M | EV / Sales 2025 * | 9 x |
P/E ratio 2024 * |
64.2
x | P/E ratio 2025 * |
51.3
x | Employees | - |
Yield 2024 * |
0.45% | Yield 2025 * |
0.45% | Free-Float | 99.03% |
Latest transcript on BIO-TECHNE Corp
Managers | Title | Age | Since |
---|---|---|---|
Kim Kelderman
CEO | Chief Executive Officer | 57 | 18-04-29 |
James Hippel
DFI | Director of Finance/CFO | 53 | 14-03-31 |
Matthew McManus
COO | Chief Operating Officer | 55 | 01-07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 68 | 02-12-31 | |
Randolph Steer
BRD | Director/Board Member | 74 | 89-12-31 |
Joseph Keegan
BRD | Director/Board Member | 71 | 17-10-25 |
1st Jan change | Capi. | |
---|---|---|
+38.39% | 39.1B | |
-7.65% | 38.76B | |
+28.28% | 31.24B | |
+13.03% | 25.9B | |
-13.50% | 25.8B | |
+45.87% | 14.06B | |
+39.08% | 13.12B | |
-11.91% | 10.68B | |
-7.58% | 9.12B |